Next-generation peptide vaccines for advanced cancer

被引：105

作者：

Yamada, Akira ^{[1
]}

Sasada, Tetsuro ^{[2
]}

Noguchi, Masanori ^{[3
]}

Itoh, Kyogo ^{[2
]}

机构：

[1] Kurume Univ, Res Ctr Innovat Canc Therapy, Canc Vaccine Dev Div, Kurume, Fukuoka 830, Japan

[2] Kurume Univ, Sch Med, Dept Immunol & Immunotherapy, Kurume, Fukuoka 830, Japan

[3] Kurume Univ, Res Ctr Innovat Canc Therapy, Div Clin Res, Kurume, Fukuoka 830, Japan

来源：

CANCER SCIENCE | 2013年 / 104卷 / 01期

关键词：

CELL LUNG-CANCER; REFRACTORY PROSTATE-CANCER; PHASE-II TRIAL; MULTIPEPTIDE MELANOMA VACCINE; METASTATIC COLORECTAL-CANCER; PULSED DENDRITIC CELLS; IMMUNOLOGICAL EVALUATION; CARCINOMA PATIENTS; IMMUNE-RESPONSES; ESTRAMUSTINE PHOSPHATE;

D O I：

10.1111/cas.12050

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Many clinical trials of peptide vaccines have been carried out since the first clinical trial of a melanoma antigen gene-1-derived peptide-based vaccine was reported in 1995. The earlier generations of peptide vaccines were composed of one to several human leukocyte antigen class I-restricted CTL-epitope peptides of a single human leukocyte antigen type. Currently, various types of next-generation peptide vaccines are under development. In this review, we focus on the clinical trials of the following categories of peptide vaccines mainly published from 2008 to 2012: (i) multivalent long peptide vaccines; (ii) multi-peptide vaccines consisting of CTL- and helper-epitopes; (iii) peptide cocktail vaccines; (iv) hybrid peptide vaccines; (v) personalized peptide vaccines; and (vi) peptide-pulsed dendritic cell vaccines. (Cancer Sci 2013; 104: 1521)

引用

页码：15 / 21

页数：7

共 57 条

[41] Randomized Multicenter Trial of the Effects of Melanoma-Associated Helper Peptides and Cyclophosphamide on the Immunogenicity of a Multipeptide Melanoma Vaccine [J].

Slingluff, Craig L., Jr. ;

Petroni, Gina R. ;

Chianese-Bullock, Kimberly A. ;

Smolkin, Mark E. ;

Ross, Merrick I. ;

Haas, Naomi B. ;

Von Mehren, Margaret ;

Grosh, William W. .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (21) :2924-2932

[42] Effect of Granulocyte/Macrophage Colony-Stimulating Factor on Circulating CD8+ and CD4+ T-Cell Responses to a Multipeptide Melanoma Vaccine: Outcome of a Multicenter Randomized Trial [J].

Slingluff, Craig L., Jr. ;

Petroni, Gina R. ;

Olson, Walter C. ;

Smolkin, Mark E. ;

Ross, Merrick I. ;

Haas, Naomi B. ;

Grosh, William W. ;

Boisvert, Marc E. ;

Kirkwood, John M. ;

Chianese-Bullock, Kimberly A. .

CLINICAL CANCER RESEARCH, 2009, 15 (22) :7036-7044

[43] Induction of p53-Specific Immunity by a p53 Synthetic Long Peptide Vaccine in Patients Treated for Metastatic Colorectal Cancer [J].

Speetjens, Frank M. ;

Kuppen, PeterJ. K. ;

Welters, Marij. J. P. ;

Essahsah, Farah ;

van den Brink, Anne Marie E. G. Voet ;

Lantrua, M. Graziella Kallenberg ;

Valentijn, A. Rob P. M. ;

Oostendorp, Jaap ;

Fathers, Lorraine M. ;

Nijman, Hans W. ;

Drijfhout, Jan W. ;

van de Velde, Cornelis J. H. ;

Melief, Cornelis J. M. ;

van der Burg, Sjoerd H. .

CLINICAL CANCER RESEARCH, 2009, 15 (03) :1086-1095

[44] Phase I trial of personalized peptide vaccination for cytokine-refractory metastatic renal cell carcinoma patients [J].

Suekane, Shigetaka ;

Nishitani, Masaaki ;

Noguchi, Masanori ;

Komohara, Yoshihiro ;

Kokubu, Takako ;

Naitoh, Masayasu ;

Honma, Shigenori ;

Yamada, Akira ;

Itoh, Kyogo ;

Matsuoka, Kei ;

Kanayama, Hiroomi .

CANCER SCIENCE, 2007, 98 (12) :1965-1968

[45] Vaccination with p53 peptide-pulsed dendritic cells is associated with disease stabilization in patients with p53 expressing advanced breast cancer; monitoring of serum YKL-40 and IL-6 as response biomarkers [J].

Svane, Inge Marie ;

Pedersen, Anders E. ;

Johansen, Julia S. ;

Johnsen, Hans E. ;

Nielsen, Dorte ;

Kamby, Claus ;

Ottesen, Svend ;

Balslev, Eva ;

Gaarsdal, Eva ;

Nikolajsen, Kirsten ;

Claesson, Mogens H. .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (09) :1485-1499

[46] First clinical trial of cancer vaccine therapy with artificially synthesized helper/killer-hybrid epitope long peptide of MAGE-A4 cancer antigen [J].

Takahashi, Norihiko ;

Ohkuri, Takayuki ;

Homma, Shigenori ;

Ohtake, Junya ;

Wakita, Daiko ;

Togashi, Yuji ;

Kitamura, Hidemitsu ;

Todo, Satoru ;

Nishimura, Takashi .

CANCER SCIENCE, 2012, 103 (01) :150-153

[47] Peptide vaccination for patients with melanoma and other types of cancer based on pre-existing peptide-specific cytotoxic T-lymphocyte precursors in the periphery [J].

Tanaka, S ;

Harada, M ;

Mine, T ;

Noguchi, M ;

Gohara, R ;

Azuma, K ;

Tamura, M ;

Yamada, A ;

Morinaga, A ;

Nishikori, M ;

Katagiri, K ;

Itoh, K ;

Yamana, H ;

Hashimoto, T .

JOURNAL OF IMMUNOTHERAPY, 2003, 26 (04) :357-366

[48] Phase I Trial of a Personalized Peptide Vaccine for Patients Positive for Human Leukocyte Antigen-A24 With Recurrent or Progressive Glioblastoma Multiforme [J].

Terasaki, Mizuhiko ;

Shibui, Soichiro ;

Narita, Yoshitaka ;

Fujimaki, Takamitsu ;

Aoki, Tomokazu ;

Kajiwara, Koji ;

Sawamura, Yutaka ;

Kurisu, Kaoru ;

Mineta, Toshihiro ;

Yamada, Akira ;

Itoh, Kyogo .

JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) :337-344

[49] Immunological evaluation of personalized peptide vaccination in refractory small cell lung cancer [J].

Terazaki, Yasuhiro ;

Yoshiyama, Koichi ;

Matsueda, Satoko ;

Watanabe, Noriko ;

Kawahara, Akihiko ;

Naito, Yoshiki ;

Suekane, Shigetaka ;

Komatsu, Nobukazu ;

Ioji, Tetsuya ;

Yamada, Akira ;

Mine, Takashi ;

Terasaki, Mizuhiko ;

Itoh, Kyogo ;

Takamori, Shinzo ;

Sasada, Tetsuro .

CANCER SCIENCE, 2012, 103 (04) :638-644

[50] Vaccination with predesignated or evidence-based peptides for patients with recurrent gynecologic cancers [J].

Tsuda, N ;

Mochizuki, K ;

Harada, M ;

Sukehiro, A ;

Kawano, K ;

Yamada, A ;

Ushijima, K ;

Sugiyama, T ;

Nishida, T ;

Yamana, H ;

Itoh, K ;

Kamura, T .

JOURNAL OF IMMUNOTHERAPY, 2004, 27 (01) :60-72

← 1 2 3 4 5 6 →